

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

Recombinant Human Thrombopoietin Injection (TPIAO®) of 3Sbio approved for pediatric ITP indication

3SBio Inc. (the “**Company**”) wishes to provide to the shareholders of the Company the attached press release in respect of the Company’s Recombinant Human Thrombopoietin Injection (TPIAO®) submitted for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents to the National Medical Products Administration (NMPA) of the PRC being approved on 2 April.

This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
12 April 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG, Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry, and Dr. ZHANG Dan as independent non-executive Directors.

Recombinant Human Thrombopoietin Injection (TPIAO®) of 3SBio approved for pediatric ITP indication

11 April 2024, Shenyang, the PRC

Leading Chinese biopharmaceutical company 3SBio Inc. (01530.HK) announced today that the Company's Recombinant Human Thrombopoietin Injection (TPIAO®) submitted for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents to the National Medical Products Administration (NMPA) of the PRC have been approved on 2 April.

TPIAO® is the Recombinant Human Thrombopoietin Injection independently developed by 3SBio, which has previously been approved for solid tumor post-chemotherapy thrombocytopenia (CIT) and primary immune thrombocytopenia (ITP) indications in adults. Currently, the Recombinant Human Thrombopoietin Injection is the first-choice second-line treatment drug recommended by PRC's ITP guidelines.

Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. Pediatric ITP is often characterized by sudden petechiae, ecchymosis or bleeding in children who are normally healthy. Occasionally, thrombocytopenia is found in patients who undergo whole blood cell counts due to other conditions. In order to meet the clinical treatment needs of pediatric ITP and respond to the national call to develop drugs for children, 3SBio launched its Phase III clinical study for pediatric ITP in a total of 10 children's hospitals and general hospitals across the country, with the overall effective rate as the main therapeutic efficacy index.

Dr. LOU Jing, Chairman and CEO of 3SBio Inc., commented, "TPIAO® has been proven to be trustworthy in long-term clinical practice, and we believe it will continue to perform well in the treatment of pediatric ITP patients. The approval of pediatric ITP indication will improve its accessibility in pediatric clinical practice and thus better meet the clinical treatment needs of pediatric ITP in China. In the future, 3SBio will remain committed to the research and development of high-quality biopharmaceuticals to benefit more patients and families."